story of the week
7-Month PSA Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With ADT With or Without Docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel
J. Clin. Oncol 2017 Dec 20;[EPub Ahead of Print], LC Harshman, YH Chen, G Liu, MA Carducci, D Jarrard, R Dreicer, N Hahn, JA Garcia, M Hussain, D Shevrin, M Eisenberger, M Kohli, ER Plimack, M Cooney, NJ Vogelzang, J Picus, R Dipaola, CJ SweeneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.